Drops for Eli Lilly and other influential companies are weighing on U.S. indexes Tuesday, even though most of the market is rising following an encouraging update on inflation.The S&P 500 was down 0.2 ...

with the S&P 500 Index SPX rising 0.25% to 6,090.27 and the Dow Jones Industrial Average DJIA falling 0.28% to 44,642.52. Eli Lilly & Co. closed $145.82 short of its 52-week high ($972.53), which ...

2024 was an excellent year for the major stock market indexes. But the Dow Jones Industrial Average ( ^DJI 0.78%) had just a ...

Dow giant Caterpillar fell on an earnings miss, while S&P 500 play Eli Lilly tumbled ... job openings well below views. The Dow Jones Industrial Average fell 0.4% in Tuesday's stock market ...

Investors scored big wins last year as the S&P 500, the Nasdaq, and the Dow Jones Industrial Average all climbed by double ... Image source: Getty Images. Eli Lilly (NYSE: LLY) is the maker of one of ...

"Eli Lilly Cuts 4Q Sales Outlook After Sluggish Growth for Incretin Drugs," published at 10:06 a.m. ET, incorrectly said the outlook was around $400 below the low end of its last estimated range ...

The Dow Jones Industrial Average rose on Tuesday as traders weighed ... they had for obesity drugs may not materialize as hoped. Lilly shares, which were approaching a trillion-dollar market ...

Warren Buffett Owns 6 Dow Jones Stocks. Here's the Best of the Bunch for Income Investors to Buy Right Now.

Eli Lilly cut its outlook for fourth-quarter revenue as the market for drugs that increase insulin levels grew slower than expected, but the company sees healthy growth in 2025 due to the success ...

Eli Lilly's outlook for sales of its blockbuster ... following the December report on producer prices. The Dow Jones Industrial Average, S&P 500, and Nasdaq all were down less than 0.5%.

Most U.S. stocks rose Tuesday following an encouraging update on inflation, though drops for Eli Lilly and other influential stocks kept indexes in check.

But the Dow Jones Industrial Average (DJINDICES ... making it the second most valuable U.S.-based healthcare company behind Eli Lilly. The stock got pummeled in December due to controversy ...